Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 60,013,352
  • Shares Outstanding, K 211,010
  • Annual Sales, $ 12,274 M
  • Annual Income, $ 2,539 M
  • 36-Month Beta 0.84
  • Price/Sales 4.88
  • Price/Cash Flow 10.48
  • Price/Book 4.27

Price Performance

See More
Period Period Low Period High Performance
1-Month
262.27 +8.44%
on 04/25/18
285.52 -0.39%
on 05/14/18
+22.26 (+8.49%)
since 04/24/18
3-Month
249.17 +14.14%
on 04/24/18
296.10 -3.95%
on 02/26/18
-8.37 (-2.86%)
since 02/23/18
52-Week
244.28 +16.43%
on 05/31/17
370.57 -23.25%
on 01/26/18
+31.08 (+12.27%)
since 05/24/17

Most Recent Stories

More News
Why is Biogen (BIIB) Up 6.7% Since Its Last Earnings Report?

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BIIB : 284.41 (+0.23%)
Should You Invest in the PowerShares Dynamic Biotechnology & Genome Portfolio (PBE)?

Sector ETF report for PBE

PBE : 51.05 (+0.55%)
ILMN : 270.83 (-0.33%)
IBB : 107.34 (+0.08%)
QGEN : 36.28 (+1.06%)
XBI : 92.73 (+0.31%)
BIIB : 284.41 (+0.23%)
Novartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents

The FDA approves Novartis' (NVS) multiple sclerosis drug Gilenya for the treatment of children and adolescents aged between 10 and 18.

LGND : 189.42 (-0.69%)
NVS : 76.17 (-0.34%)
TEVA : 21.63 (+2.27%)
BIIB : 284.41 (+0.23%)
Biogen and American Express rise; Symantec plunges

NEW YORK (AP) — Stocks that moved substantially or traded heavily on Friday:

SYMC : 20.99 (-1.55%)
FLS : 43.19 (-0.51%)
BIIB : 284.41 (+0.23%)
Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1

The biotech sector was in focus over the last five trading sessions as several bigwigs like Gilead and Vertex, among others reported results while some others provided pipeline updates.

VRTX : 156.97 (-0.01%)
GILD : 67.53 (-0.94%)
REGN : 294.61 (-0.24%)
AMGN : 177.96 (-1.10%)
ALXN : 117.14 (-0.84%)
BIIB : 284.41 (+0.23%)
What's in the Cards for Ionis (IONS) This Earnings Season?

Ionis Pharmaceuticals (IONS) earns $30 million in license payments from AstraZeneca. Spinraza witnesses strong first quarter as announced by Biogen in its earnings release.

EBS : 50.61 (-0.90%)
IONS : 45.23 (+2.59%)
VNDA : 17.20 (+1.78%)
BIIB : 284.41 (+0.23%)
Biogen and Neurimmune Announce Option Exercise for Alzheimer's Disease Investigational Treatment Aducanumab

Biogen (Nasdaq: BIIB) and Neurimmune announced today that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab,...

BIIB : 284.41 (+0.23%)
Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1

Alkermes (ALKS) posts wider than expected loss in the first quarter of 2018. However, sales beat estimates.

PTGX : 6.61 (+2.96%)
LGND : 189.42 (-0.69%)
ALKS : 45.42 (-0.48%)
BIIB : 284.41 (+0.23%)
Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales

The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.

LLY : 82.71 (+0.04%)
INCY : 66.67 (+0.15%)
IONS : 45.23 (+2.59%)
PRTA : 14.86 (+3.77%)
CALA : 5.40 (+3.85%)
AMGN : 177.96 (-1.10%)
BIIB : 284.41 (+0.23%)
Biogen Inc Set to Possibly Pullback After Yesterday's Rally of 2.55%

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $262.27 to a high of $274.40. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $267.66...

BIIB : 284.41 (+0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade BIIB with:

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 287.56
1st Resistance Point 285.99
Last Price 284.41
1st Support Level 282.32
2nd Support Level 280.22

See More

52-Week High 370.57
Fibonacci 61.8% 322.33
Fibonacci 50% 307.42
Fibonacci 38.2% 292.52
Last Price 284.41
52-Week Low 244.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar